Etomidate Mechanism of Action and Adrenal Suppression
Etomidate produces hypnosis by enhancing GABA-A inhibition in the brain. It also reduces adrenal steroid production, particularly by inhibiting 11-beta-hydroxylation. Those effects happen through different mechanisms. A patient can wake up while the adrenal effect is still present.
Sachi, CRNA
CRNA

In This Article (7 sections)
- How does etomidate make the patient unconscious?
- How does it reduce cortisol production?
- Why is etomidate often chosen when blood pressure is a concern?
- Does adrenal suppression mean it must never be used in sepsis?
- How would you explain the choice in a patient with low pressure?
- Our Final Thoughts
- Add another induction agent to the comparison
Practice explaining this drug in two parts: what happens in the brain, and what happens in the adrenal gland. It gives you a way to work beyond a one-line description of the drug.
The induction-agent lessons in the CRNA Club clinical library through the seven-day platform trial help you compare those effects. Learn what happens in the brain and adrenal gland before stopping at “etomidate is hemodynamically stable.”
How does etomidate make the patient unconscious?
GABA is a neurotransmitter that slows neuronal activity. GABA-A is a ligand-gated ion channel, meaning a signal binds the receptor and changes ion movement through the channel.
Etomidate enhances that inhibitory activity. The neurons become less excitable, producing hypnosis for anesthesia induction.
Does hypnosis cover pain too? No. Etomidate doesn’t provide analgesia. The induction plan still needs to address pain, the airway and the other parts of the procedure.
You may also see myoclonus, brief involuntary movements. Movement after etomidate doesn’t automatically mean an epileptic seizure. The etomidate prescribing information describes induction use, myoclonus and adrenal suppression.
How does it reduce cortisol production?
The adrenal cortex produces cortisol through a sequence of enzyme-driven reactions. Etomidate interferes with a late step, 11-beta-hydroxylation. Less cortisol is produced, and the gland’s response to stimulation is reduced.
The patient isn’t making less cortisol simply because they’re asleep. The drug is affecting the steroid-production process separately from its effect on GABA-A receptors.
For studying, draw the two effects next to each other:
- Brain: enhanced GABA-A inhibition reduces neuronal activity and produces hypnosis.
- Adrenal cortex: inhibited 11-beta-hydroxylation reduces steroid synthesis and the cortisol response.
Review both in the clinical learning library. Then ask which effect you’re describing when you talk about onset, awakening or the stress response. They don’t all end at the same time.
Why is etomidate often chosen when blood pressure is a concern?
Compared with some induction agents, it often causes less cardiovascular depression during induction. That can be useful when a patient has little cardiovascular reserve.
But less depression doesn’t mean pressure can’t fall. A critically ill patient may already have too little circulating volume. Other medications, airway intervention and the switch to positive-pressure ventilation can affect the circulation too.
So if pressure drops, check those contributors. Etomidate’s relative cardiovascular stability is one reason to consider it, while the patient still needs a plan for induction-related hypotension.
Does adrenal suppression mean it must never be used in sepsis?
No. Reduced steroid production is a demonstrated drug effect. Saying one induction dose inevitably increases mortality is a different claim, and you shouldn’t treat the two as equivalent.
The choice depends on the patient, the alternatives and the airway plan. Explain the adrenal risk alongside the immediate cardiovascular problem rather than calling etomidate always safe or always wrong in sepsis.
Prolonged infusion is a separate issue. Etomidate isn’t intended as a prolonged ICU sedative infusion because it suppresses endogenous cortisol and aldosterone production. A short hypnotic action doesn’t make continued exposure appropriate.
How would you explain the choice in a patient with low pressure?
In this fictional case, a patient needs urgent intubation and has low pressure with poor cardiac reserve. You need to consider both the induction drug and the circulatory effects of managing the airway.
Etomidate may offer less cardiovascular depression than some alternatives. It also has the adrenal effect you’ve just traced. Compare those considerations with the patient’s physiology and the available agents.
An interview answer should explain both mechanisms and how you’d prepare for hypotension. After induction, reassess circulating volume, vasopressor needs and the effects of ventilation. Choosing the drug doesn’t finish the hemodynamic assessment.
Our Final Thoughts
Draw the brain effect and adrenal effect beside each other, then cover the notes and talk through both. Give the enzyme step another pass if you need to. The aim is to explain why awakening and recovery of the cortisol response aren’t the same question.
Add another induction agent to the comparison
The induction-agent teaching in the seven-day CRNA Club platform trial lets you continue the comparison. Put etomidate beside propofol or ketamine in one patient and explain the considerations you’d reassess.


